CClinicalTrials.gg
Sign In
Status unknownNCT02443844Updated May 14, 2015

Comparison of Medical and Surgical Treatments of Benign Prostate Hyperplasia in Patients Who Have Low Grade Non Muscle Invasive Bladder Cancer for Tumour Recurrence and Progression

A Phase 4 interventional study of Transurethral Resection and Tamsulosin in Bladder Cancer, sponsored by Diskapi Teaching and Research Hospital. Status unknown at 1 site in Turkey. Open to male participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2015-05-14.

Sponsored by Diskapi Teaching and Research Hospital · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2015), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
Male
01

Study summary

The purpose of this study is to compare medical and surgical treatments of benign prostate hyperplasia in patients who have non muscle invasive bladder cancer for tumour recurrence and progression.

02

Conditions studied

  • Bladder Cancer

Keywords

  • BPH
  • bladder cancer
  • treatment
  • recurrence
  • progression
03

In context

Urinary Bladder Neoplasms

1,616 studies on the registry are indexed under Urinary Bladder Neoplasms; 421 are open to participants now.

This study's planned enrollment of 40 is below the median of 60 across 1,163 interventional studies indexed under Urinary Bladder Neoplasms.

Browse Urinary Bladder Neoplasms studies →

Lead sponsor

Diskapi Teaching and Research Hospital is the lead sponsor of 101 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Inclusion criteria

  • Patients who have non muscle invasive bladder cancer male patients patients between 40-80 years old

Exclusion criteria

Exclusion Criteria:

  • Patients who have previous prostate surgery Patients who have muscle invasive bladder cancer
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    First group

    Patients taken tamsulosin for benign prostate hyperplasia who have non muscle invasive bladder cancer

    Drug: Tamsulosin

  • Active comparator
    Second Group

    Patients taken transurethral resection prostatectomy for benign prostate hyperplasia who have non muscle invasive bladder cancer

    Procedure: Transurethral Resection

Interventions

  • ProcedureTransurethral Resection

    Endoscopic treatment of bladder cancer

  • DrugTamsulosin

    Medical treatment for benign prostate hyperplasia

    Also known as: alfa blocker treatment

06

What researchers measure

Primary outcomes

  1. Recurrence

    Bladder cancer recurrence rate

    Time frame: 3 years

Secondary outcomes

  1. Progression

    Bladder cancer progression rate

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
  • Turkish Ministry of Health Dıskapı Yıldırım Beyazıt Training and Research Hospital
    Ankara, 06110, Turkey
    • Nihat Karakoyunlu, MD · Contact · nkarakoyunlu@gmail.com · 00905324747134
    • Nihat Karakoyunlu, MD · Principal investigator
    Recruiting
08

References and documents

Publications

  • Li S, Zeng XT, Ruan XL, Wang XH, Guo Y, Yang ZH. Simultaneous transurethral resection of bladder cancer and prostate may reduce recurrence rates: A systematic review and meta-analysis. Exp Ther Med. 2012 Oct;4(4):685-692. doi: 10.3892/etm.2012.660. Epub 2012 Aug 9. PubMed 23170127 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 14, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02443844
Lead sponsor
Diskapi Teaching and Research Hospital
Responsible party
Nihat Karakoyunlu (MD, Diskapi Teaching and Research Hospital) — Principal investigator
First posted
May 14, 2015
Start date
Feb 2015
Primary completion
Feb 2018 (estimated)
Completion
Feb 2020 (estimated)
Last update
May 14, 2015

Study contacts

Nihat Karakoyunlu, MD
Contact
nkarakoyunlu@gmail.com
00905324747134
Nihat Karakoyunlu, MD
principal investigator · Dıskapı TRH

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Urinary Bladder Neoplasms→

Other studies from this sponsor

Diskapi Teaching and Research Hospital

Start the discussion